Related Experiment Video
Updated: Jan 6, 2026
Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
Published on: November 24, 2014
The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models
Marc Garcia-Moure1,2,3, Naiara Martinez-Velez1,2,3, Marisol Gonzalez-Huarriz1,2,3
1Navarra's Health Research Institute (IDISNA), Pamplona, Spain.
Abstract:
Last advances in the treatment of pediatric tumors has led to an increase of survival rates of children affected by primitive neuroectodermal tumors, however, still a significant amount of the patients do not overcome the disease. In addition, the survivors might suffer from severe side effects caused by the current standard treatments. Oncolytic virotherapy has emerged in the last years as a promising alternative for the treatment of solid tumors. In this work, we study the anti-tumor effect mediated by the oncolytic adenovirus VCN-01 in CNS-PNET models. VCN-01 is able to infect and replicate in PNET cell cultures, leading to a cytotoxicity and immunogenic cell death. In vivo, VCN-01 increased significantly the median survival of mice and led to long-term survivors in two orthotopic models of PNETs. In summary, these results underscore the therapeutic effect of VCN-01 for rare pediatric cancers such as PNETs, and warrants further exploration on the use of this virus to treat them.
Insights
Oncolytic adenovirus VCN-01 shows promise for treating pediatric primitive neuroectodermal tumors (PNETs). This therapy demonstrated anti-tumor effects in cell cultures and significantly improved survival in animal models.
Area of Science:
- Oncology
- Virology
- Gene Therapy
Background:
- Pediatric primitive neuroectodermal tumors (PNETs) have improved survival rates, but challenges remain with treatment efficacy and side effects.
- Oncolytic virotherapy presents a promising alternative for solid tumor treatment, including rare pediatric cancers.
Purpose of the Study:
- To evaluate the anti-tumor efficacy of the oncolytic adenovirus VCN-01 in central nervous system (CNS) PNET models.
Main Methods:
- In vitro studies assessed VCN-01's ability to infect and replicate in PNET cell cultures, inducing cytotoxicity and immunogenic cell death.
- In vivo studies utilized orthotopic PNET models in mice to evaluate VCN-01's impact on survival.
Main Results:
- VCN-01 effectively infected and replicated in PNET cells, causing cell death and triggering an immune response.
- In vivo, VCN-01 significantly increased median survival and generated long-term survivors in orthotopic PNET models.
Conclusions:
- VCN-01 exhibits significant therapeutic potential against rare pediatric cancers like PNETs.
- Further research into VCN-01 as a treatment for PNETs is warranted.
More Related Videos
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:27Tumor Immunotherapy
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...